"Onyx only generated $362 million in sales last year, but AMGN expects its blood cancer drug Kyprolis to be a multi-billion dollar blockbuster"
If PAB can hitch its wagon to this, then the skys the limit.
I look forward to the ASH conference exposure.
Oscar
ann: data from final cohort of patients, page-45
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $7.419K | 2.372M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 56 | 40557809 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 26688875 | 13 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |